Table 4. Comparative Cost-Effectiveness of Statin Use for Primary Prevention of Coronary Heart Disease Relative to Next-Broadest Strategy.

	ATP III	ACC-AHA	Age/Sex-Based
Total Additional Persons Acted On	8.76 m*	12.3 m	28.8 m
Total Cost	-$10.7 b	-$3.85 b	-$11.5 b
Treatment costs	$8.29 b	$13.3 b	$13.4 b
Screening costs	$2.65 b	$3.71 b	$2.69 b
Savings from events averted	-$19.0 b	-$17.2 b	-$24.9 b
Incident CHD Events Averted	341,000	236,000	421,000
QALYs Saved	253,000	183,000	269,000
Lives Saved	42,300	43,100	49,000
Total Cost per QALY (ICER)	Cost-saving	Cost-saving	Cost-saving
NNT per QALY	35	68	108
NNT per Life Saved	205	285	589

^*7.6 million started on statins de novo; 1.2 with prior dose intensified.